Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study
Conditions
- Peripheral T-cell Lymphomas
Interventions
- DRUG: GDP
- BIOLOGICAL: Endostar
Sponsor
Nanjing NingQi Medicine Science and Technology Co., Ltd.
Collaborators